about
Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.Assessment of cardiac resynchronisation therapy in patients with wide QRS and non-specific intraventricular conduction delay: rationale and design of the multicentre randomised NICD-CRT study.Statin and Atrial Fibrilation: When does it work?Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials.Programming implantable cardioverter-defibrillators in primary prevention: higher or later.Successful 'quadrangular' pacing in a non-responder patient to cardiac resynchronization therapy.How to define valvular atrial fibrillation?Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator.Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves.Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Société française de cardiologie et Société française de gériatrie et gérontologie.Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Société Française de Cardiologie and Société Française de Gériatrie et Gérontologie.High risk in atrial fibrillation following an ablation procedure: the wide usefulness of the CHADS(2) score.A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry.Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study.Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation: Outcomes From a Controlled Nonrandomized Study.Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial FibrillationOral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.Prognosis in Familial Atrial Fibrillation.[Left atrial appendage closure in atrial fibrillation].Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure.Ventricular pacing through coronary sinus in patients with tricuspid prosthesis.Outcomes after ablation for typical atrial flutter (from the Loire Valley Atrial Fibrillation Project).Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy.Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke.Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort.Clinical impact of an additional left ventricular lead in cardiac resynchronization nonresponders: the V3 trial.Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1.Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial.CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis.Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications.Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.Major ST-segment elevation hiding acute severe pancreatitis.Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study.
P50
Q28275973-89A10839-46C6-43B4-80EF-B4D8AFD3BF01Q33167996-29B9571B-EAD7-4795-82BD-72C3B1CB9484Q33844478-01C5A64E-9560-4845-A707-9597F44D7943Q37454970-00EA7B7D-E014-4881-810A-06E90B0CC9BBQ37495979-E230D17B-C8D1-4B6C-9F21-C372C722EC0FQ38060519-1528A09E-71D7-4049-A89D-177B9A0F5635Q38212284-00B99B32-E5D4-41AA-8EF2-C736364434DBQ38272586-7AFBC83D-5780-4E85-939E-34083B68F7B5Q38549124-E6323954-B49B-4283-B156-4FA7A5A20C0EQ38692639-A992F9E7-0C91-4DF8-A0D5-A3A57FE9F1F4Q38846506-33DB8A64-37D7-4C28-A70D-FF322A56F537Q39090624-4CB5EBEE-973D-494B-A45C-C250557879EEQ39368909-269F0A2B-2AFB-48AA-AE6E-CC7C95DBA351Q39422196-B40C6095-3FCF-46A4-A7B8-CD0D624D28ECQ39546937-9AD36451-8982-4B12-AAF6-CFD82F814F2FQ40213531-A56799B6-C92D-473E-B380-A2242A9E8495Q40556805-FA055409-9E9A-4D97-BA97-D6E29A526D1BQ40594118-DA2FCACC-1F9E-4A50-A1ED-37A409B8403EQ40673233-39F36EE0-B245-4B73-8A11-23632D3FF6EEQ41203031-AB3B1C5C-588F-4B60-AC0F-90961BF719DDQ41278761-F2A4EC3E-B660-4341-AD75-115C35BC96E9Q41725911-5181ED7B-D958-4AAD-BB05-152E9A223E7DQ42334336-120DFBC6-C6D0-453F-A0F8-DA625646B09BQ43487534-092137A9-9E36-4EAB-98F9-7A021822A007Q44101149-6DD75294-6DA0-45B2-BB72-DD9D3959F041Q44830034-6FDD288B-3199-42AB-9681-73FE01C1CEB1Q44910778-C48B90C4-A0A2-4976-9FAA-C1991865DFE2Q47755223-D8F2FDAA-A4F9-44A5-B8E1-F754792AB808Q48130046-1E67106A-4558-4026-8E12-43A5AFA04C3BQ48548343-98C392EA-F173-4023-92A9-8D2F93070474Q49486468-61B4E8AB-01B8-42E6-B9A1-9F660A6B4F5EQ50195061-060D3C24-AE00-4258-A211-87D1771A8D0BQ50934656-9785CE53-6187-41BD-9B99-F87741E71A8AQ51182458-71ECEDE1-0827-40AC-80EB-9B47F99C1B38Q51551293-5D9B812D-25FD-4D5D-9BCD-C0387540ED12Q51798446-2B7D1486-E30D-460E-BF86-A7B16C492E21Q52340243-2387F866-C959-4653-8A5A-F67D3C5A6F98Q52655608-60CF31A2-B67F-4373-A5BD-54B7C5F57451Q53319377-540DA711-B11D-42AC-B677-800F9496A6CCQ54232354-0EAD88B5-BFD3-4BA7-B26D-98A9CAFE9346
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
N Clementy
@ast
N Clementy
@en
N Clementy
@es
N Clementy
@nl
N Clementy
@sl
type
label
N Clementy
@ast
N Clementy
@en
N Clementy
@es
N Clementy
@nl
N Clementy
@sl
prefLabel
N Clementy
@ast
N Clementy
@en
N Clementy
@es
N Clementy
@nl
N Clementy
@sl
P106
P1153
10243474800
P31
P496
0000-0002-7415-0787